Jaffna Sheen Stevenson
Family · San Bernardino, CANPI 1669820254
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,177 and has fallen 51.9% since, to $1,047 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$1K
- GSK$1K
- Boehringer Ingelheim$1K
- AstraZeneca$394
- Regeneron Healthcare Solutions, Inc.$343
- Grifols USA, LLC$290
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,56997%
- Education$1803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 40 | $1,237 |
| GSK | 59 | $1,079 |
| Boehringer Ingelheim | 51 | $1,054 |
| AstraZeneca | 24 | $394 |
| Regeneron Healthcare Solutions, Inc. | 13 | $343 |
| Grifols USA, LLC | 11 | $290 |
| Merck | 14 | $289 |
| Mylan Specialty L.p. | 11 | $208 |
| Axsome Therapeutics, Inc. | 8 | $167 |
| Pulmonx Corporation | 8 | $160 |
| Baxter Healthcare | 6 | $137 |
| Insmed, Inc. | 6 | $129 |
| Phadia US Inc. | 6 | $126 |
| Advanced Respiratory, Inc | 5 | $123 |
| Sanofi | 6 | $118 |
| United Therapeutics Corporation | 5 | $117 |
| Actelion Pharmaceuticals US, Inc. | 6 | $107 |
| Boston Scientific | 2 | $101 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| ANI Pharmaceuticals, Inc. | 3 | $80 |
| Electromed, Inc. | 4 | $78 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $78 |
| Jazz Pharmaceuticals Inc. | 2 | $59 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| La Jolla Pharmaceutical Company | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $22 |
| Novo Nordisk | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$6,748 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $271,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 216 | $152,432 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $30,497 |
| Spiriva RespimatTiotropium Bromide | 34 | $24,044 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $21,470 |
| RybelsusSemaglutide | 13 | $11,712 |
| Wixela InhubFluticasone Propion/Salmeterol | 59 | $8,525 |
| Spiriva HandihalerTiotropium Bromide | 12 | $7,706 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $7,602 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $7,491 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $7,395 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 240 | $7,246 |
| EliquisApixaban | 12 | $6,695 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,624 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,054 | $302,26469 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,079 | $190,531297 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $394 | $27,03752 claims |
| Novo NordiskRybelsus | $18 | $11,71213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Bernardino
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.